Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Carpinelli, Patrizia, Ceruti, Roberta, Giorgini, Maria Laura, Cappella, Paolo, Gianellini, Laura, Croci, Valter, Degrassi, Anna, Texido, Gemma, Rocchetti, Maurizio, Vianello, Paola, Rusconi, Luisa, Storici, Paola, Zugnoni, Paola, Arrigoni, Claudio, Soncini, Chiara, Alli, Cristina, Patton, Veronica, Marsiglio, Aurelio, Ballinari, Dario, Pesenti, Enrico, Fancelli, Daniele, Moll, Jürgen·2007·Molecular Cancer Therapeutics

Abstract

PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition–related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status–dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser10 is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers. [Mol Cancer Ther 2007;6(12):3158–68]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-07-0444

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 245

Metadata

Authors
Carpinelli, P., Ceruti, R., Giorgini, M. L., Cappella, P., Gianellini, L., Croci, V., Degrassi, A., Texido, G., Rocchetti, M., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Arrigoni, C., Soncini, C., Alli, C., Patton, V., Marsiglio, A., Ballinari, D., Pesenti, E., Fancelli, D., & Moll, J.
Venue
Molecular Cancer Therapeutics
Published
2007-12-01
Volume
6
Issue
12
Pages
3158-3168
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2125294721
Cited by
245
References
0
FWCI
8.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-07-0444
The paper
Carpinelli, P., Ceruti, R., Giorgini, M. L., Cappella, P., Gianellini, L., Croci, V., Degrassi, A., Texido, G., Rocchetti, M., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Arrigoni, C., Soncini, C., Alli, C., Patton, V., Marsiglio, A., Ballinari, D., . . . Moll, J. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-07-0444

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.